Moderna, Inc. Stock price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:46:23 2023-11-29 pm EST Intraday chart for Moderna, Inc. 5-day change 1st Jan Change
79.45 USD +1.62% +1.43% -55.86%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
Sales 2023 * 6,493 M Sales 2024 * 4,511 M Capitalization 29.81 B
Net income 2023 * -5,412 M Net income 2024 * -2,319 M EV / Sales 2023 *
3,77x
Net cash position 2023 * 5,347 M Net cash position 2024 * 3,795 M EV / Sales 2024 *
5,77x
P/E ratio 2023 *
-5,69x
P/E ratio 2024 *
-12,8x
Employees 3,900
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.05%
1 week+2.06%
Current month+5.03%
1 month+7.71%
3 months-31.22%
6 months-38.10%
Current year-55.58%
More quotes
1 week
75.66
Extreme 75.66
81.12
1 month
62.55
Extreme 62.55
81.12
Current year
62.55
Extreme 62.55
207.51
1 year
62.55
Extreme 62.55
217.25
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 2011
Director of Finance/CFO 46 2022
President 47 2012
Members of the board TitleAgeSince
Director/Board Member 64 2018
Director/Board Member 73 2020
Director/Board Member 66 2019
More insiders
Date Price Change Volume
23-11-29 79.22 +1.33% 1 352 210
23-11-28 78.18 +0.59% 2,240,038
23-11-27 77.72 -1.02% 2,960,110
23-11-24 78.52 +0.45% 2,152,974
23-11-22 78.17 +1.34% 2,203,917

Delayed Quote Nasdaq, November 29, 2023 at 09:39 am EST

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
78.18USD
Average target price
139.90USD
Spread / Average Target
+78.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer